August 2019

Nicholas J. Vogelzang, MD, FASCO, FACP, discusses groundbreaking developments that have transformed the treatment of prostate cancer, as well as current issues in urology.

My hopes were to be that rare individual who went through life never having to see the sharp end of a Bard-Parker scalpel. That fantasy is about to come to an abrupt end.

Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.